Drug intelligence / Profile preview

PIK7

Development stage
Preclinical
Lead developer
National Medical Research Center for Cardiology
Modality
Peptides
Administration
Intravenous
01

Overview

PIK7 is a proteolytically stable peptide inhibitor of myosin light chain kinase (MLCK) designed to prevent endothelial hyperpermeability and vascular leakage. Developed by the National Medical Research Center of Cardiology (named after Academician E.I. Chazov) in Russia, PIK7 is based on the structure of MLC11-19, a competitive MLCK inhibitor, but modified to improve stability against plasma peptidases. In preclinical models, PIK7 has demonstrated antiedematous effects by suppressing vascular hyperpermeability caused by myocardial ischemia-reperfusion injury, suggesting potential as an adjuvant therapy for myocardial infarction. Additionally, PIK7 has been shown to inhibit platelet adhesion to fibrinogen- and collagen-coated surfaces under high blood flow conditions, indicating potential antiatherothrombotic applications.

Other names
KD-KRAARATS-NH2KD-KRAARATS-NH-2KD-KRAARATS-NH 2KD-KRAARATS
02

Targets

MLCK (Myosin light chain kinase)

Beyond the preview

Go deeper on PIK7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PIK7.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call